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PURPOSE: A novel quantitative magnetic resonance imaging (MRI) method, namely, temporal diffusion
spectroscopy (TDS), was used to detect the response of tumor cells (notably, mitotic arrest) to a specific
antimitotic treatment (Nab-paclitaxel) in culture and human ovarian xenografts and evaluated as an early imaging
biomarker of tumor responsiveness. METHODS: TDS measures a series of apparent diffusion coefficients (ADCs)
of tissue water over a range of effective diffusion times, which may correspond to diffusion distances ranging
from subcellular to cellular levels (~3-20 μm). By fitting the measured ADC data to a tissue model, parameters
reflecting structural properties such as restriction size in solid tumors can be extracted. Two types of human
ovarian cell lines (OVCAR-8 as a responder to Nab-paclitaxel and NCI/ADR-RES as a resistant type) were treated
with either vehicle (PBS) or Nab-paclitaxel, and treatment responses of both in vitro and in vivo cases were
investigated using TDS. RESULTS: Acute cell size increases induced by Nab-paclitaxel in responding tumors were
confirmed by flow cytometry and light microscopy in cell culture. Nab-paclitaxel–induced mitotic arrest in treated
tumors/cells was quantified histologically by measuring the mitotic index in vivo using a mitosis-specific marker
(anti-phosphohistone H3). Changes in the fitted restriction size, one of the parameters obtained from TDS, were
able to detect and quantify increases in tumor cell sizes. All the MR results had a high degree of consistency with
other flow, microscopy, and histological data. Moreover, with an appropriate analysis, the Nab-paclitaxel–
responsive tumors in vivo could be easily distinguished from all the other vehicle-treated and Nab-paclitaxel–
resistant tumors. CONCLUSION: TDS detects increases in cell sizes associated with antimitotic-therapy–inducedReceived 4 February 2016; Revised 1 April 2016; Accepted 14 April 2016
© 2016 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an
open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/ by-
nc-nd/4.0/).
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388 Detection of Treatment-Induced Mitotic Arrest Jiang et al. Neoplasia Vol. 18, No. 6, 2016mitotic arrest in solid tumors in vivo which occur before changes in tissue cellularity or conventional diffusion MRI
metrics. By quantifying changes in cell size, TDS has the potential to improve the specificity of MRI methods in
the evaluation of therapeutic response and enable a mechanistic understanding of therapy-induced changes
in tumors.
Neoplasia (2016) 18, 387–397Introduction
Tumor progression relies upon abnormally frequent cell division.
Microtubules play an important role in the process of cell division, so
targeting microtubules with appropriate anticancer drugs continues to
be a successful approach for cancer chemotherapy [1]. Several new
drugs that target microtubules are being developed or are already in
clinical trials. Among current microtubule-targeted agents, Nab-
paclitaxel (Abraxane) is widely used to treat breast, ovarian, lung, and
pancreatic cancers and Kaposi’s sarcoma [2,3]. Despite the clinical
success of this class of pharmaceuticals, drug resistance is a common
occurrence [1]. Therefore, it is highly desirable to detect the early
response of individual patients’ tumors to successful, or unsuccessful,
antimitotic therapies so that treatment regimens can be altered
adaptively in time to minimize unnecessary toxicity and treatment
delays. Measuring changes in tumor size by x-ray computed
tomography or magnetic resonance imaging (MRI) [4], the current
standard method to assess the treatment response of solid tumors,
suffers from fundamental limitations [5,6]. Fine-needle aspiration has
been used to detect paclitaxel-induced mitotic arrest in breast cancer.
However, this approach has limitations which include the invasive
nature of the procedure, applicability, and insufficient tissue
collection [7]. Sequential positron emission tomography imaging
using F-18-fluorodeoxyglucose has been reported to assess metabolic
changes in ovarian cancer in a small group of patients receiving
paclitaxel treatments, but the sensitivity and specificity of this method
need further investigation [8].
Diffusion-weighted MRI (DW-MRI) is a noninvasive imaging
technique that has previously been used to assess tumor treatment
response without the need for any hazardous radiation or exogenous
probes. DW-MRI reveals information on the random (Brownian)
motion of water molecules in tissues. Water movement in tissues is
modified by interactions with, e.g., hydrophobic cellular membranes,
intracellular organelles, andmacromolecules, so the observed rate of water
diffusion in cellular tissues is less than that in free solutions. The apparent
diffusion coefficient (ADC) that is measured by practical MRI methods
thereby provides information on those factors that hinder or restrict free
diffusion including tissue cell density and cell sizes, extracellular-space
tortuosity, and the integrity of cellular membranes [9]. Preclinical and
clinical data have indicated the potential role of DW-MRI in the
monitoring tumor response to therapy [10–12]. It has been reported that
ADC values for human breast cancer tumor xenografts increase in
response to paclitaxel treatment and occur earlier than significant tumor
volume reductions [13]. However, ADC values are potentially affected
by multiple factors including tissue cellularity, cell size, nuclear size,
cell membrane integrity, and the presence of necrosis [14,15], which
are all commonly involved in the tumor response to therapies.
Interpretation of these changing ADC values must, therefore, be made
with caution [14,16].The dynamics of the response to antimitotic drug have been investigated
by time-lapse microscopy in culture [17]. As illustrated in Supplementary
Figure 1, the treated tumor cells first enter mitotic arrest and then either
initiate apoptosis or exit into an abnormal G1-like state withmultiple small
nuclei. Most multinucleated cells cannot recover normal nuclear
morphology and eventually die. Mitotic arrest has therefore long been
established as a hallmark of the cellular response to antimitotic drugs. It has
been widely used as a biomarker in human and rodent cancer models by
scoring histology sections or stained biopsies [18,19]. A noninvasive
imaging readout of this biomarker would allow a specific and accurate
quantification of tumor response to antimitotic therapies which potentially
occurs earlier than measureable tumor regression.
Temporal diffusion spectroscopy (TDS) is a specific class of
DW-MRI which can characterize tissue microstructure more
comprehensively than conventional single-ADC measurement and
which may allow a more mechanistic understanding of chemother-
apy-induced cellular changes [20–24]. Rather than measuring a single
average ADC over a relatively long diffusion time (~20-50
milliseconds), TDS measures ADC values over a range of effective
diffusion times, corresponding to diffusion distances ranging from
subcellular to cellular levels (~3-20 μm). These are achieved by using
time-varying (typically cosinusoidally oscillating) diffusion-sensitizing
gradients in which the effective diffusion time is determined by the
characteristic frequency of the gradient waveforms, and hence
measured ADC values are expressed as a function of a spectral
frequency. By fitting the measured ADC spectra to a simplified tissue
model, three parameters associated with mean cell size, the tortuosity
of the extracellular space, and a measure of intracellular structural
complexity, respectively, can be extracted. It may be noted that both
mitotic arrest and multinucleation act to increase mean tumor cell size
[25]. The derived spectral parameter associated with cell size is
hypothesized to reflect these dimensional increases and accordingly
may provide a specific and accurate quantification of cellular response
to antimitotic therapy. In the current study, this hypothesis is
evaluated in cell cultures in vitro and in human ovarian cancer
xenografts in vivo. The MR results are supported by flow cytometry,
light microscopy, and histological analyses.
Materials and Methods
Cancer Model and Treatment
Nab-paclitaxel is a mitotic inhibitor used for treatment of breast,
lung, pancreatic, and ovarian cancers [1,3]. Two types of human
ovarian cancer cell line, OVCAR-8 and NCI/ADR-RES, were used in
the current study. It has been reported that Nab-paclitaxel mitigates/
reverses the development of OVCAR-8 tumors by slowing/blocking
mitosis and inducing apoptosis, whereas NCI/ADR-RES is resistant
to Nab-paclitaxel [26].
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Cell Preparation. Human ovary carcinoma cell lines (OVCAR-8)
were purchased from American Type Culture Collection (Manassas,
VA), and the drug-resistant counterpart NCI/ADR-RES was
obtained from the Drug Development Program at National Cancer
Institute, and cultured in RPMI Medium 1640 supplemented with
10% FBS, 50 U/ml of penicillin, and 50 g/ml of streptomycin
(Invitrogen, CA) under standard culture conditions in a humidified
incubator maintained at 5% CO2 and 37°C. OVCAR-8 and NCI/
ADR-RES cells were cultured in 60-mm dishes to full confluence and
then treated with either PBS or nab-paclitaxel at two different
concentrations (100 and 500 nM) for 24 hours. All the cells were
harvested by trypsinization, washed with PBS buffer, and resuspend-
ed with PBS/0.1% BSA. InMR experiments, cells were fixed with 4%
paraformaldehyde in PBS for over 2 hours. After fixation, cells were
washed, and approximately 35 million cells were centrifuged at 2000g
× 2 minutes in a 0.65-ml of Eppendorf tube to obtain a tight cell
pellet. All the liquid on the top was carefully removed, and the tube
with cell pellet was used for MRI experiments. In flow cytometry
experiments, cells were fixed with 3× volume of cold (−20°C)
absolute ethanol and kept at −20°C. Before flow cytometry analysis
(FACS), the cells were spun down and washed twice with PBS,
resuspended with propidium iodide (PI) staining solution (3.8 mM
sodium citrate, 50 μg/ml of PI, 0.5 mg/ml of RNase A in PBS) to a
final cell concentration about 1 × 106 cell/ml, and incubated 3 or
more hours at 4°C before FACS analysis. Samples were analyzed on a
flow cytometer FACSCalibur (BD Biosciences, Mountain View, CA)
with a minimum of 10,000 cells analyzed per sample. The data were
collected with CellQuest software (BD Biosciences) and analyzed
with Matlab R2013b.
NMR Measurements In Vitro. All measurements were performed
on a Varian DirectDrive horizontal 4.7-T magnet (Varian Inc., Palo
Alto, CA) equipped with a self-shielded SGRAD 115/60/S gradient
system (Magnex Scientific Limited, Yarnton, Oxford, UK). A 40-mm
inner diameter millipede volume coil was used for RF transmission
and reception. As described above, OVCAR-8 and NCI/ADR-RES
cells were treated with three different concentrations of Nab-
paclitaxel with four samples at each concentration. ADC values for
both conventional DWI (using a pulsed gradient spin echo [PGSE]
sequence) as well as for TDS (using an oscillating gradient spin echo
[OGSE] acquisition) were measured. Two gradient b values (0 and
400 s/mm2) were used in both PGSE and OGSE measurements. The
OGSE pulse sequence used two apodized cosine-modulated gradients
as described in references [21,27]. For PGSE experiments, diffusion
gradient durations were δ = 4 milliseconds and separation Δ = 48
milliseconds. The OGSE measurements were made using gradient
frequencies from 50 to 350 Hz with an interval of 50 Hz. Note that
the echo times (echo time = 67 milliseconds) for both PGSE and
OGSE measurements were the same to minimize relaxation effects.
In Vivo Experiments
Animals and Tumor Induction. All procedures were approved by
our Institutional Animal Care and Usage Committee at Vanderbilt
University. Female Athymic nude mice (Harlan Laboratories, Inc.,
Indianapolis, IN) were used for the study and observed daily and
weighed weekly to ensure that interventions were well tolerated.
Experiment Outline. Because the current study focuses on
ovarian cancer, only female athymic nude mice were used. Twelve
mice were inoculated with OVCAR-8 cells into the right hind limb,and 10 mice were inoculated with NCI/ADR-RES cells. When a
tumor reached a size of 200 to 300 mm3, the mouse underwent
pretreatment MRI scans followed by the first treatment. This time
point was defined as day 0. The 12 OVCAR-8 tumor-bearing mice
were treated with either Nab-paclitaxel (n = 7) or drug vehicle PBS (n
= 5) every other day at 15 mg/kg for 4 days. The 10 NCI/ADR-RES
tumor-bearing mice were treated with either Nab-paclitaxel (n = 5) or
PBS (n = 5) every other day at 15 mg/kg for 4 days. The injection of
drug or drug vehicle was administered by a single intraperitoneal
injection. Each treated mouse with either Nab-paclitaxel or PBS was
imaged at pretreatment on day 0 and after two treatments on day 4,
and was sacrificed for collection of tumor tissues immediately after the
second imaging time point.
In Vivo MR Imaging. Animals were anesthetized with a 2%/98%
isoflurane/oxygen mixture before and during scanning, and the
magnet bore temperature was kept at 32°C using a warm-air feedback
system. Stretchable medical tapes were used to ensure the proper
positioning of hind limbs and tumors and to restrain movement
caused by respiration, as well as to reduce motion-induced artifacts in
the image data. Respiratory signals were monitored using a small
pneumatic pillow placed under the mouse abdomen, and respiration
gating (SA Instruments, Stony Brook, NY) was applied to further
reduce motion artifacts. A doped water phantom (5 mM CuSO4) was
placed beneath the animal at thermal equilibrium with the magnet
bore temperature, and its ADC value was measured to monitor the
consistency of ADC measurements. The details of animal settings
have been reported previously [22].
Both OGSE and PGSE sequences were implemented using a
two-shot echo planar imaging acquisition using the same MRI
equipment as described above. The imaging parameters were as
follows: for PGSE experiments, diffusion gradient durations were δ =
4 milliseconds and separation Δ = 48 milliseconds. The OGSE
sequence used gradient frequencies from 50 to 350 Hz with δ/Δ = 20/
25 milliseconds, corresponding to effective diffusion times approx-
imately from 5 to 0.7 milliseconds. Two b values (0 and 400 s/mm2)
were used for both PGSE and OGSE acquisitions. Multiple axial
slices covering the entire tumor were acquired with a slice thickness of
2 mm. The matrix size was 128 × 64 with field of view = 40 × 20 mm,
yielding an isotropic in-plane resolution of 312.5 μm. Note that the
echo times (echo time = 67milliseconds) for all ADCmeasurements were
again the same to minimize relaxation effects. In addition, multiple axial
slices, T2-weighted images covering the same volume as ADC
measurements were collected with the following parameters: time to
repetition = 4 seconds; time to echo = 0.05 seconds; slice thickness =
2 mm; the matrix size was 128 × 64 with field of view = 40 × 20 mm.
Histology. All the animals were sacrificed immediately after the
last MRI session. The tumors were then dissected, cut into small
pieces of approximately 2 mm in thickness, and immersed in formalin
for 24 hours. All the tumor tissues were embedded in paraffin. To
quantify mitotic index, proliferation, and apoptosis, three single,
8-μm-thick tissue sections were taken from each piece of tissue and
stained with anti-phosphohistone H3 (PHH3), Ki-67 antibody, and
caspase-3 antibody, respectively, according to standard protocols of
the manufacturer’s manual. All the stained slides were scanned by a
Leica SCN400 Slide Scanner with a magnification of 20 to generate
high-resolution digital images. A purpose-written segmentation
algorithm was implemented to calculate percentages of caspase-3–
activated area and Ki-67–positive cells, mitotic index (the number of
PHH3-positive cells divided by the number of total cells), and
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for the entire slides.
Diffusion Models and Data Analysis. Tumor volumes were
calculated from T2-weighted Images. As only two imaging time
points 4 days apart were selected, central tumor necrotic cores
(defined by very high T2W MR signals, high ADC values, and flat
ADC spectra independent on frequencies due to the high water
content) were only found in a few tumors. These necrotic cores were
excluded from the diffusion and histology analyses to better
characterize the treatment response of viable tumor tissues.
The ADC values were then calculated for the nonnecrotic tumor
region on each slice using Eq. (1):
ADC ¼ − log I b2 ¼ 400ð Þ
I b1 ¼ 0ð Þ
 
= b2−b1ð Þ ð1Þ
Here I(b) is the diffusion-weighted signal intensity with a specific b
value (here, 0 or 400 s/mm2).
If tumors are assumed to consist of impermeable spherical cells, the analytical
expression of ADC values for TDS diffusion measurements is given by:
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f is the oscillation frequency, δ is the gradient duration,Δ is the separation
of two diffusion gradients. The terms Bn and λn are structure-dependent
parameters that depend on sphere diameters [21]. The accuracy of Eq. (2)
has been validated by computer simulations [21] and phantom
experiments [28]. Note that the ADC represented by Eq. (2) drops to
zero at long diffusion times or low frequencies (i.e., ADCsphere[f = 0] = 0)
because of complete restriction. However, in biological tissues, the
presence of permeable cell membranes and the nature of the extracellular
space tortuosity lead to a nonzero value for ADCsphere(f = 0). To count for
these effects, a modified tumor ADC model was used as
ADCtumor fð Þ ¼ ADCsphere f ; d;Dinf −D0
 þ D0 ð3Þ
whereDinf andD0 represent the tumor ADC values at infinitely high and
zero frequencies, respectively. The mean ADC spectra of the tumor
region on each slice were fit to the Eq. (3). The restriction size d represents
the mean restriction dimension in tumors, which is associated with mean
tumor cell size because cell membranes have been reported as the
dominant restriction barriers in tissues [29]. In tumor tissues,D0 andDinf
aremainly determined by the extracellular tortuosity [30] and intracellular
diffusion coefficient, respectively.Statistical Analysis
The differences in cell sizes derived from FACS and microscopy,
and MR-derived measures of restriction among the different types ofcell samples treated with Nab-paclitaxel at different concentrations
(Figures 1–3) were summarized using means and standard deviations and
compared by one-way analysis of variance (ANOVA). The differences in
three fitted parameters from the TDS data (d, Dinf, and D0) and
conventional (PGSE-derived) ADC values for the two types of tumors
treated with either PBS or Nab-paclitaxel (Figure 5) were summarized
using means and standard deviations and compared by a Kruskal-Wallis
test. All the tests were two-sided, and a false discovery rate (FDR)–
adjusted P value of .05 or less was taken to indicate statistical significance.
Statistical analyses were performed using Matlab R2013b.
Results
Flow Cytometry And Microscopy Analysis
Flow cytometry measures multiple physical characteristics of single
cells as they flow in a fluid stream through a beam of light. Light scattering
occurs when a single cell deflects incident laser light. The width of
forward-scattered light (FSC-W) is proportional to cell size [31].
Figure 1A shows the distributions of FSC-W (sample size is 6100) for
OVCAR-8 (responder) and NCI/ADR-RES (resistant) cells treated with
various concentrations of Nab-paclitaxel (0, 100, and 500 nM). FSC-Ws
for OVCAR-8 cells increase continuously as the concentration goes
higher (P b .0001), indicating antimitotic treatment–induced increases in
cell size. No significant differences (P N .05) in FSC-W are observed
between PBS-treated and 100 nM Nab-paclitaxel–treated NCI/
ADR-RES cells, whereas FSC-W of 500 nM Nab-paclitaxel–treated
NCI/ADR-RES is significantly larger than the other two cohorts (P b
.0001), indicating that NCI/ADR-RES is responsive only to a very high
concentration of Nab-paclitaxel.
Flow cytometry also distinguishes cells in different phases of the
cell cycle by quantifying different DNA contents they contain. The
emission light intensity of PI-labeled cells is proportional to the
amount of DNA present in the cells, and its histogram is used to
calculate the percentage of cells in the different parts of the cell cycle
[31]. The DNA content of G2/M cells is about twice that of G0/G1
cells because the chromosomes have been doubled during S phase.
Polypoid cells sometimes appear in cancer cells, which have more
DNA content than G2/M cells. DNA fragmentation is one of the
hallmarks of apoptosis [32]. As a result, sub-G0 cells are usually
associated with apoptotic cells. As shown in Figure 1C and
Supplementary Table 1, the percentages of G2/M Nab-paclitaxel–
treated OVCAR-8 cells continue to increase from 32% at 0 nM to
64.2% at 100 nM and to 76.3% at 500 nM, indicating a significant
treatment-induced G2/M phase arrest as expected. NCI/ADR-RES
cells treated with 100 nM Nab-paclitaxel show a very slightly increase
from 34% to 36.5% in the population of G2/M cells. By contrast,
NCI/ADR-RES cells treated with 500 nM Nab-paclitaxel exhibit a
large population (62.2%) of G2/M cells, again demonstrating that
NCI/ADR-RES is more responsive to higher concentration of
Nab-paclitaxel. It is also noted that populations of sub-G0 cells
associated with apoptotic cells are small for the cell samples that have
significant mitotic arrest, suggesting that mitotic arrest may be the
first cellular response to Nab-paclitaxel treatment.
The absolute cell sizes were measured by light microscope
(Figure 1B, n = 620). The mean cell size of OVCAR-8 keeps
increasing with increasing concentrations of Nab-paclitaxel (P b
.0001), whereas the Nab-paclitaxel–treated NCI/ADR-RES
cells swell measurably only at the concentration of 500 nM (P =
.004).
Figure 1. Cell size changes measured by flow cytometry and light microscopy and cell cycle analysis. (A) Box-and-whisker plots of the
FSC-W for OVCAR-8 and NCI/ADR-RES treated with various concentrations of Nab-paclitaxel (0, 100, and 500 nM). The sample size of
each cohort is 6100. (B) Box-and-whisker plots of the cell size measured by light microscopy for OVCAR-8 and NCI/ADR-RES treated with
various concentrations of Nab-paclitaxel (0, 100, and 500 nM). The sample size of each cohort is 620. For all the box-and-whisker plots, the
25th to 75th percentiles are blocked by the boxp; the black and red bands inside the box are the median and mean, respectively; and the
whiskers mark the SD. ****P b .0001 as measured by one-way ANOVA with an FDR posttest. (C) Histograms of the emission light
intensity of PI-labeled NCI/ADR-RES and OVCAR-8 cells treated with Nab-paclitaxel at 0 (black line), 100 (blue line), and 500 nM (red line).
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undergo apoptosis. It is known that cells significantly increase their
sizes during the M phase. Here, our flow cytometry and light
microscope analyses confirm that Nab-paclitaxel–treated OVCAR-8
cells undergo significant mitotic arrest and show increases in cell size
in response to the antimitotic treatment.
Histological Analysis
Representative PHH3-stained slides for either Nab-paclitaxel or
PBS-treated OVCAR-8 and NCI/ADR-RES tumors are shown in
Supplementary Figure 2. The brown stain represents mitotic cells.
The percentage of mitotic cells (the number of PHH3-positive cells
divided by the total number of cells) is calculated from the
high-resolution digital images of each PHH3-stained slide (Supple-
mentary Figure 3). As shown in Figure 2B, Nab-paclitaxel–treated
OVCAR-8 tumors have a significantly higher percentage of mitotic
cells than PBS-treated OVCAR-8 tumors (P = .04). No significant
difference is observed between Nab-paclitaxel– and PBS-treated
NCI/ADR-RES tumors.
The percentage of caspase-3–activated area was calculated from the
high-resolution digital images of each caspase-3–stained slide.Nab-paclitaxel–treated OVCAR-8 tumors have the highest percent-
age of caspase-3–activated area (~35%) among all the cohorts (P =
.04), indicating treatment-induced apoptosis (Figure 2C).
Nab-paclitaxel–treated OVCAR-8 tumors have a lower average
cellularity than PBS-treated OVCAR-8 tumors, but the difference is
not significant (Figure 2A). There are no significant differences in
percentages of Ki-67–positive cells between Nab-paclitaxel– and
PBS-treated tumors (Figure 2D). Although some studies have
reported increases in percentages of Ki-67–positive cells in
paclitaxel-treated tumors [33,34], many other animal and human
studies did not observe significant changes in proliferative activity as
measured by Ki-67 in tumor tissues following paclitaxel [35–37]. A
possible explanation is that the changes in Ki-67 expression are highly
dependent on the choices of observation time points posttreatment.
Changes in Tumor Cell Size in Response to Antimitotic Treatment
quantified by TDS Restriction Size In Vitro Experiments
The fitted mean restriction size of Nab-paclitaxel–treated
OVCAR-8 cells increased significantly (P = .04) with increasing
drug concentration (Figure 3A). By contrast, there were no significant
changes in restriction size of Nab-paclitaxel–treated NCI/ADR-RES
Figure 2. Cellularity (A), percentages of mitotic cells (B), caspase-3–activated area (C), and percentages of Ki-67–positive cells (D) for
Nab-paclitaxel–/PBS-treated OVCAR-8 and NCI/ADR-RES tumors. *P b .05 as measured by one-way ANOVA with an FDR posttest.
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treated OVCAR-8 cells reflects the increase of tumor cell size in
response to antimitotic treatment, which is confirmed by 1) changes in
mean cell size measured by light microscopy (Figure 1B) and 2) changes
in the FSC-W measured by flow cytometry (Figure 1A). Differences in
restriction size betweenPBS-treatedNCI/ADR-RES andOVCAR-8 cells
as shown in Figure 3Amay result from the intrinsic differences in cell size
between different types of cells. The absolute cell sizes are reported to be
16.07 ± 2.42 μm and 14.24 ± 2.71 μm for NCI/ADR-RES and
OVCAR-8 cells [38,39], respectively.
Figure 3B shows that the fitted Dinf of 500 nM Nab-paclitaxel–
treated OVCAR-8 cells is significantly lower than that of PBS-treated
OVCAR-8 cells (P = .04), likely because of the increased structural
complexity inside arrested cells in M phase. The fitted D0 of
Nab-paclitaxel–treated OVCAR-8 cells (Figure 3C) shows a
decreasing trend as the drug concentration increases. The fitted D0
and PGSE-derived ADC of 100 nM Nab-paclitaxel–treated NCI/
ADR-RES cells are significantly lower than those of PBS-treated
NCI/ADR-RES cells (P b .05). These decreases in either D0 or
PGSE-derived ADC indicate a decreased tortuosity of the extracel-
lular space. In our cell experiment, all the cells were treated firstly with
either PBS or Nab-paclitaxel and then centrifuged to create tight cell
pellets with the same speed and time. Morphological properties of the
extracellular space depend on how the cells are arranged during
centrifugation and may correlate with the cell size distribution. As
shown in Figure 1C, two types of cells treated with the same
concentration of Nab-paclitaxel have similar DNA content distribu-tion, which is roughly the same as the cell volume distribution.
Interestingly, the D0 and PGSE-derived ADC values for OVCAR-8
and NCI/ADR-RES treated with the same concentration of
Nab-paclitaxel are almost the same. Although the cell pellet is not
an appropriate system to investigate the treatment-induced changes in
tortuosity of the extracellular space, it fulfills our purpose to measure
the treatment-induced changes in cell size.
In Vivo Experiments
Figure 4A shows ADCmaps of a representative slice obtained using
TDS at frequencies ranging from 0 to 350 Hz overlaid on the
corresponding T2-weighted images. ADC values for the tumor region
increase as the frequency increases, indicating less restrictions to water
molecules at higher frequencies or shorter diffusion times. Mean-
while, ADC values for the water phantom do not change with the
frequency, confirming that the ADC changes in tumor are not an
instrument artifact. The ADC changes for an OVCAR-8 tumor
before and after a 4-day Nab-paclitaxel treatment are quantitatively
shown in Figure 4B. A typical ADC spectrum for tumor is
characterized by a low ADC value at zero frequency followed by a
rapid increase that reaches a plateau, quantified by three spectral
parameters D0, d, and Dinf, respectively. The three parameters for
nontreated and Nab-paclitaxel–treated OVCAR-8 are d = 5.92 μm,
Dinf = 1.58 μm
2/ms, and D0 = 0.47 μm
2/milliseconds and d = 9.22
μm, Dinf = 1.36 μm
2/ms, and D0 = 0.37 μm
2/milliseconds,
respectively. The increase of d from 5.92 to 9.22 μm reflects the
treatment-induced increase in tumor cell size.
Figure 3. Fitted d (A), Dinf (B), D0 (C), and PGSE-derived ADC (D) for OVCAR-8 and NCI/ADR-RES cell pellets treated with Nab-paclitaxel at
0, 100, and 500 nM. *P b .05 as measured by one-way ANOVA with an FDR posttest.
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.05) differences in tumor growth among PBS/Nab-paclitaxel–treated
tumors. Figure 5 summarizes the percentage changes before and afterFigure 4. (A) ADCmaps of a representative slice through tumor and a
T2-weighted MR images. The water phantom was placed beneat
measurements. (B) Representative ADC values of an OVCAR-8 tumo
using TDS and conventional PGSE acquisitions at frequencies ranging
The fitted parameters for nontreated (blue) and Nab-paclitaxel–treated
μm2/ms and d= 9.22 μm, Dinf = 1.36 μm
2/ms, andD0 = 0.37 μm
2/ms
diffusion time of 48 milliseconds is plotted as the ADC at a correspoPBS/Nab-paclitaxel treatments in the fitted spectral parameters and
PGSE-derived ADC for all the tumors. Six of seven Nab-paclitaxel–
treated OVCAR-8 tumors show an increase (N20%) of fitted meanwater phantom at frequencies ranging from 0 to 350 Hz, overlaid on
h the mouse to monitor the accuracy and consistency of ADC
r at day 0 (nontreated) and day 4 (Nab-paclitaxel–treated) obtained
from 0 to 350 Hz. Solid lines represent the fits using Eqs. (1) to (3).
(red) OVCAR-8 are d= 5.92 μm,Dinf = 1.58 μm
2/ms, andD0 = 0.47
, respectively. It is noted that the ADCmeasured using PGSE with a
nding frequency of 5.2 Hz.
Figure 5. Percentage changes in d (A),Dinf (B),D0 (C), and PGSE-derived ADC (D) for OVCAR-8 and NCI/ADR-RES tumors receiving a 4-day
treatment of either Nab-paclitaxel or PBS at a dose of 15 mg/kg.
Figure 6. Scatter plot of the percentages of change in two spectral
parameters (restriction size d and D0) for all the treated tumors.
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than that of the other three cohorts and consistent with our in vitro
observations. These six Nab-paclitaxel–treated OVCAR-8 tumors
also show a decrease of fitted D0 (Figure 5C), indicating a decrease of
extracellular volume due to the increase of cell size. Interestingly,
there is one Nab-paclitaxel–treated OVCAR-8 tumor that showed a
~25% decrease of mean restriction size and a ~20% increase of D0. It
is also notable that this tumor had the largest percentage of caspase-3–
activated area (65%) in all the treated-responder tumors. A possible
explanation is that the tumor reached a later stage of pathological
response to treatment so that most cells underwent apoptosis. The cell
shrinkage during apoptosis may have overcome any increase in cell
size that resulted from mitosis inhibition as illustrated in Supple-
mentary Figure 1. There were no significant differences in the fitted
Dinf and PGSE-derived ADC among two types of tumors treated with
either Nab-paclitaxel or PBS (P N .05).
Figure 6 is a scatter plot of the percentages of changes in two
spectral parameters (restriction size d and D0) for all the animals. Two
perpendicular axes (percentage change of D0 = 0, d = 20%,
respectively) divide the plane into four areas. Six of seven
Nab-paclitaxel–treated OVCAR-8 tumors and one of five Nab-
paclitaxel–treated NCI/ADR-RES tumors are inside the bottom-right
quadrant which has a decreased D0 and N20% increase of d. The one
Nab-paclitaxel–treated OVCAR-8 tumor which is not inside the
bottom-right quadrant had the largest region undergoing apoptosis, a
later effect of the treatment, among the Nab-paclitaxel–treated
OVCAR-8 tumors. The one Nab-paclitaxel–treated NCI/ADR-RES
tumor which is inside the bottom-right quadrant had the largest
region undergoing apoptosis among the Nab-paclitaxel–treated NCI/ADR-RES tumors, suggesting that it may start to respond to the
treatment. Therefore, a combination of decreased D0 and increase of
d may be an early indicator of effective antimitotic therapies.
Discussion
Reliable and sensitive methods for assessing the response of tumors
to antimitotic therapies, a widely used treatment option for various
cancers, are critical to minimize unnecessary toxicity and treatment
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at an early stage of treatment, and are also valuable for assisting the
development of new drugs that inhibit mitosis. Mitotic arrest is a
natural biomarker of tumor response to antimitotic therapy, but
currently, it can be characterized only by scoring histology sections or
stained biopsies in human and rodent cancer models. In this paper,
TDS, combining a single long diffusion time conventional PGSE
acquisition with a series of OGSE measurements, is demonstrated to
quantify microstructural changes (notably, increases in cell size) in
tumors as an early response marker for antimitotic therapy. The
increases in cell size quantified by restriction size d, one of the spectral
parameters derived from TDS measurements, occur when no
significant changes in either cellularity (Figure 2A) or tumor volume
regression (Supplementary Figure 4) are observed. Flow cytometry,
light microscopy, and histological analyses correlate these increases in
cell size with treatment-induced mitotic arrest. In addition, the
combination of restriction size andD0, a spectral parameter associated
with tissue cellularity, is shown to distinguish the Nab-paclitaxel–
treated responsive tumors from either Nab-paclitaxel–treated resistant
tumors or PBS-treated responsive tumors, indicating TDS as a
potential imaging marker for early detection of successful antimitotic
therapies.
The concentrations of Nab-paclitaxel used in the cell experiment
were 100 and 500 nM, at which the effects of paclitaxel on mitosis in
culture are well understood [40]. Mitotic arrest increases cell size,
whereas cell death is often coupled with a decrease of cell size. Our in
vitro data, including flow cytometry, light microscopy, and TDS
analyses, all detected an increase in cell size for OVCAR-8 cells treated
with Nab-paclitaxel for 24 hours, consistent with 1) our cell cycle
analysis indicating a significant G2/M phase arrest and 2) a reported
finding that cells at saturating paclitaxel concentrations (typically N
100 nM) rarely die without first entering mitotic arrest that can last
24 hours or longer depending on the cell line [40].
For our in vivo treatment study, a moderate dosing scheme (15
mg/kg, every other day) was chosen and demonstrated significant
mitotic arrest and apoptosis induction in responsive tumors
(Figure 3). Although cell shrinkage is one of the hallmarks in cell
morphologic changes during apoptosis and may overcome the
increase in cell size resulted from mitotic arrest, it occurs rather late
in apoptosis. In the experiment, six of seven Nab-paclitaxel–treated
OVCAR-8 tumors showed an increase (N20%) of fitted mean
restriction size d. There is one Nab-paclitaxel–treated OVCAR-8
tumor which had the largest percentage of caspase-3–activated area
(65%) in all the treated-responder tumors; it showed a ~25%
decrease of mean restriction size. This implies that mitotic arrest is the
first cellular response to antimitotic therapies, followed by apoptosis,
consistent with previous findings. Increases in cell size dominate the
overall imaging results for responsive tumors that have not reached a
later stage of pathological response to treatment. Therefore, TDS
method is reliable to detect mitosis arrest at early stages of response to
antimitotic therapies. In addition, TDS method may provide a
comprehensive means to monitor temporal dynamic changes of
tumor status following treatment.
A single ADC value measured with a relatively long diffusion time
has been shown to negatively correlate with cellularity and has
previously been used to monitor tumor response to therapy [9,14,41].
However, our PGSE-derived ADC values with a diffusion time of 48
milliseconds do not differentiate the Nab-paclitaxel–treated respon-
sive tumors from PBS-treated responsive tumors and PBS/Nab-paclitaxel–treated resistant tumors. The histological data showed that
the Nab-paclitaxel–treated responsive tumors have a lower mean
cellularity than the PBS-treated responsive tumors, but the difference
is not significant. In addition, ADC values are affected by multiple
microstructural features simultaneously not limited to cellularity. The
increases in cell size that resulted from mitotic arrest reduce the
extracellular spaces and thus decrease the PGSE-derived ADC values,
which may compromise the increase in ADC values due to cell loss.
Therefore, the conventional measurements of a single averaged ADC
at a long diffusion time may not be specific enough to characterize
accurate pathologic changes in tumors following treatments, which in
turn decreases the sensitive to assess the early therapeutic response of
tumors. By contrast, the proposed TDS method enhances the
specificity of DW-MRI to specific cellular changes such as cell size,
which in turn provides a means to assess tumor status more accurately
following treatments.
Our in vitro results show that the fitted restriction sizes are
significantly smaller (~50%) than cell sizes measured by light
microscope for the same type of cell line receiving the same treatment.
This discrepancy is not too surprising, as the simplified model
assumes spherical cells or a single size parameter. Moreover, cells
observed by light microscope float on a drop of PBS solution without
pressure from neighboring cells. By contrast, cells in tumors are
tightly packed which may reduce the extent of cell swelling during
mitosis arrest. Secondly, the restriction size characterizes the mean
length scale of the restrictions in biological tissues. In tumors, the cells
are tightly packed, and accordingly, the restriction size should be
dominated by cell size. However, pathway lengths in extracellular
spaces, which are much smaller than cell sizes, also contribute to the
derived restriction size and may average down the estimated
restriction dimension. A more complex two-compartment model
for fitting diffusion spectra has been proposed to extract mean cell size
as well as intracellular volume fraction. It has proven successful in
well-characterized cell cultures [42] and fixed tissues [43]. It may
provide an accurate way to measure cell size in further in vivo
treatment studies, but this more accurate approach requires longer
scanning times with multiple b values compared with the current
approach.
The range of diffusion times or gradient frequencies used in TDS
determines the length scales of the structural variations to which the
method is sensitive. The measured ADC is able to probe finer
structural changes as the effective diffusion time becomes shorter or
the frequency becomes higher. But acquiring diffusion-weighted
signals at very high frequency needs very high gradient strengths. For
example, a gradient strength of 68 G/cm, much higher than the
maximum gradient strength applicable in current clinical settings, was
used in our study to measure ADC at 350 Hz. Fortunately, our MR
findings indicate that the restriction size and D0 are more valuable
than Dinf in detecting structural changes in response to antimitotic
therapies. The restriction size characterizes how ADC rises in
response to an increase in the frequency and D0 represents the ADC
at very low frequency. As reported in our previous cell size
measurement study, the rising portion of ADC spectra almost ends
before the frequency reaches 150 Hz for cells with size from 5 to 20
μm, covering the cell size range of most solid tumors. Therefore, the
current acquisition scheme of TDS can be optimized by reducing the
highest frequency (for example, from 350 Hz to 150 Hz) if tumor cell
size is the primary target for monitoring treatment response. It will
significantly lower the maximum gradient strength required and
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effective clinical translation.
The location of tumor formation is relevant in mimicking human
diseases. The subcutaneous xenograft model of ovarian cancer used in
this paper provides a platform to verify the feasibility of TDS imaging
method in detecting treatment-induced mitotic arrest noninvasively.
Note that this model is not ideal for survival studies determining the
efficacy of therapies. Either intraperitoneal or orthotopic xenograft
model has been suggested to better mimic various stages of ovarian
cancer and is useful to investigate the influences of treatments on
survival rates [44]. However, this is out of the main scope of the
current work that focuses on the development and validation of a
novel imaging method for detection of mitosis arrest. In the future
studies, it is interesting to investigate performance of TDS method in
assessing therapeutic response using either an intraperitoneal or
orthotopic xenograft mouse model.
Microcirculatory perfusion of blood within capillaries was assumed
negligible in the current study. This assumption has been used in
many treatment studies using DW-MRI [16,9] because the perfusion
fraction of tissues is usually much smaller than the diffusion fraction
of tissues. In cases where effects that resulted from tumor angiogenesis
on ADC measurements cannot be assumed negligible, the current
PGSE/OGSE sequences can be modified to acquire perfusion-free
MR signals by inserting a PGSE filter with a small b value at the
beginning of the sequence [45].
In this proof-of-concept study, TDS is shown to provide an in vivo
detection of mitotic arrest which is an early cellular marker for
antimitotic therapies. Therefore, TDS may assist to investigate many
critical questions regarding antimitotic therapies. For example, the
dose-dependent effects of antimitotic drugs on cell biology in vivo
[17,18] and how the cellular responses correlate with therapeutic
outcome are not fully understood. Profiling the time course changes
in TDS-derived restriction size d in response to treatments with
multiple dosing schemes may provide more insights into these
questions. It should be emphasized that applications of TDS are not
limited in antimitotic therapies only. Based on its capability of
measuring specific cellular morphologic changes, this method can be
useful in characterizing tumor response to other therapies which
induce microstructural variations in tumor tissues. For example, it has
been reported that cell swelling is the first manifestation of various
chemo/radiotherapy-induced cell injuries [14,15]. Also, cell shrinkage
is a typical feature of apoptosis, which is a common target for many
anticancer therapies [46,47]. A recent study reported in vitro
detection of apoptosis by measuring ADC values of normal and
apoptotic cells at a broad range of effective diffusion times [48].
Therefore, TDS may have a wide array of applications for detecting
tumor response to various therapies and greatly enhance the
specificity of MRI methods in the evaluation of therapeutic response.
Conclusion
In the work reported herein, a novel MRI-based approach to assessing
tissue water diffusion over varying time scales was used to examine the
cellular response to Nab-paclitaxel in culture and human ovarian
cancer xenografts. The Nab-paclitaxel–induced increase in cell size
was observed using flow cytometry and light microscopy in cultured
cells. Histological analyses confirmed that Nab-paclitaxel induces
mitotic arrest and apoptosis in tumors. Both in vitro and in vivo MR
data obtained using TDS demonstrated that the restriction size d
obtained from ADC spectra is able to quantify the increase in cell sizeassociated with mitotic arrest and multinucleation. Moreover, the
combination of restriction size and D0 is shown to distinguish the
Nab-paclitaxel–treated responsive tumors from either Nab-paclitaxel–
treated resistant tumors or PBS-treated responsive tumors, indicating
TDS as a potential imaging marker in early detection of successful
antimitotic therapies. Conventional DW-MRI using PGSE sequences
was also implemented in the study for detecting treatment response.
However, the ADC at diffusion time = 48 milliseconds, a common
value used in PGSE acquisitions, does not differentiate the
Nab-paclitaxel–treated responsive tumors from PBS-treated responsive
tumors and PBS/Nab-paclitaxel–treated resistant tumors.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2016.04.006.
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